A5043261871- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Lung Cancer Research Studies
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Pharmacological Effects and Toxicity Studies
- Glycosylation and Glycoproteins Research
- Lung Cancer Treatments and Mutations
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer Mechanisms and Therapy
University of Arkansas for Medical Sciences
2023-2024
Michigan State University
2019-2022
McLaren Health Care
2022
McLaren Regional Medical Center
2019-2022
University of Arizona
2018-2020
Lahore University of Management Sciences
2015
We present an unsupervised method to find lexical variations in Roman Urdu informal text.Our includes a phonetic algorithm UrduPhone, featurebased similarity function, and clustering Lex-C.UrduPhone encodes roman strings their equivalent representations.This produces initial grouping of different spelling word.The function incorporates word features context.Lex-C is variant k-medoids that group variations.It threshold balance the number clusters maximum similarity.We test our system on two...
e20034 Background: Bispecific T-cell engager (BiTE) antibodies are currently being studied for various hematological malignancies including relapsed and refractory multiple myeloma (RRMM). BiTE that target CD3 on T cells antigens GPRC5D, BCMA or FcRH5 in RRMM patients (pts). Methods: A comprehensive literature search was done Pubmed, Embase, Cochrane. The data presented conferences (ASH, ASCO) were also included. Results: Six clinical trials evaluating anti-BCMA, anti RRMM. Madduri et al....
The aim of our study is to evaluate risk factors associated with the development C. difficile infection (CDI) in hematopoietic stem cell transplant (HSCT) patients, determine its incidence and report outcomes CDI patient population.We performed a retrospective review medical records adult HSCT recipients diagnosed between 2013 2016 at center. Logistic regression models were used relationship odds CDI.The overall patients was 9.4%. higher allogeneic (20%) versus autologous (4.8%). No...
Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple cancers, including cervical cancer, non-small cell lung cancer (NSCLC), renal carcinoma, bladder squamous head neck cancer. Pneumonitis rare but known complication of pembrolizumab treatment NSCLC. The median time frame its appearance 2.8 months. However, we present case pneumonitis appearing within 48 hours. patient presented with rapidly progressive...
Introduction Multiple myeloma (MM) lacks curative therapy. Therefore, researchers continue to conduct studies in an effort improve progression-free survival (PFS) and overall (OS). Maintenance therapy (MT) after autologous stem cell transplant (ASCT) was extensively studied the last decade now considered a standard approach.Areas covered This review evaluated evidence updates on various maintenance agents newly diagnosed multiple (NDMM) ASCT. Articles were searched PubMed Embase that...
BACKGROUND:Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary neuroendocrine cancers (SCNECs) are treated regimens used SCLCs. Tumor lysis syndrome (TLS) solid SCLCs and SCNECs Lurbi use has not been reported the literature so far. CASE REPORT:We report a case of Lurbi-induced TLS patient SCNEC cecum single intravenous dose 3.2 mg/m2. She presented to hospital...